BioAge Labs Inc.

NASDAQ: BIOA · Real-Time Price · USD
4.00
-0.05 (-1.23%)
At close: Jun 03, 2025, 3:59 PM
3.99
-0.13%
After-hours: Jun 03, 2025, 04:20 PM EDT

BioAge Labs Statistics

Share Statistics

BioAge Labs has 35.85M shares outstanding. The number of shares has increased by null% in one year.

Shares Outstanding 35.85M
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Institutions (%) 64.22%
Shares Floating n/a
Failed to Deliver (FTD) Shares 980
FTD / Avg. Volume 0.41%

Short Selling Information

The latest short interest is 1.74M, so 4.86% of the outstanding shares have been sold short.

Short Interest 1.74M
Short % of Shares Out 4.86%
Short % of Float 5.71%
Short Ratio (days to cover) 10.28

Valuation Ratios

The PE ratio is -0.87 and the forward PE ratio is -1.78. BioAge Labs's PEG ratio is 0.04.

PE Ratio -0.87
Forward PE -1.78
PS Ratio 0
Forward PS n/a
PB Ratio 0.19
P/FCF Ratio -1.2
PEG Ratio 0.04
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for BioAge Labs.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 12.86, with a Debt / Equity ratio of 0.03.

Current Ratio 12.86
Quick Ratio 12.86
Debt / Equity 0.03
Debt / EBITDA -0.11
Debt / FCF -0.17
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee n/a
Profits Per Employee $-1,146,919.35
Employee Count 62
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by null% in the last 52 weeks. The beta is 0.77, so BioAge Labs's price volatility has been higher than the market average.

Beta 0.77
52-Week Price Change n/a
50-Day Moving Average 3.91
200-Day Moving Average n/a
Relative Strength Index (RSI) 49.6
Average Volume (20 Days) 236,593

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -78.19M
Net Income -71.11M
EBITDA -78.19M
EBIT -73.48M
Earnings Per Share (EPS) -6.63
Full Income Statement

Balance Sheet

The company has 354.35M in cash and 8.7M in debt, giving a net cash position of 345.64M.

Cash & Cash Equivalents 354.35M
Total Debt 8.7M
Net Cash 345.64M
Retained Earnings -252.81M
Total Assets 343.84M
Working Capital 301.07M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -51.52M and capital expenditures -366K, giving a free cash flow of -51.89M.

Operating Cash Flow -51.52M
Capital Expenditures -366K
Free Cash Flow -51.89M
FCF Per Share -4.84
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

BIOA does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for BIOA is $5, which is 25% higher than the current price. The consensus rating is "Hold".

Price Target $5
Price Target Difference 25%
Analyst Consensus Hold
Analyst Count 4
Stock Forecasts

Scores

Altman Z-Score 2.06
Piotroski F-Score 4